Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension of TVP-1012 1 mg in early Parkinson's disease without levodopa
jRCT2080222709Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2015
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rasagiline in Parkinson's disease (PD), sponsored by Takeda. Primary endpoint: Primary safety outcomes. Started Jan 2015; status: completed.
02
Drugs
rasagiline
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on jRCT2080222709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222709.